[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588926":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":20,"responsibleParty":34,"collaborators":7,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":7,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":56,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Taichung Veterans General Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"RADIATION","PET\u002FMRI","This single-center prospective observational study targets patients pathologically diagnosed with nasopharyngeal carcinoma (NPC) and clinically staged as cT3-4\u002FN2-N3. Participants will first undergo standard whole-body 18F-FDG PET\u002FCT, followed by localized 18F-FDG PET\u002FMRI of the head and neck within 4 hours. Both imaging procedures will be performed according to standard clinical protocols to ensure data consistency and comparability.\n\nPET\u002FMRI data will be independently interpreted by an experienced nuclear medicine physician and a radiologist. The sensitivity, specificity, and staging accuracy for detecting distant metastases will be analyzed. In cases of disagreement, a third physician will mediate to reach a consensus.\n\nThe study team will also record the operational time, direct costs, and potential issues encountered during the examination process for both imaging modalities. All participants will be followed for at least one year to validate imaging results and assess correlation",[14],{"name":15,"role":16,"phone":17,"phoneExt":18,"email":19},"Yi-Chun Liu, MD","CONTACT","886-4-23592525","5601","b9202080@vghtc.gov.tw",[21],{"facility":5,"status":7,"city":22,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Taichung","Taiwan","TW",{"type":26,"coordinates":27},"Point",[28,29],120.6839,24.1469,{"lat":29,"lon":28},[32],{"name":15,"role":16,"phone":33,"phoneExt":18,"email":19},"886-23592525",{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100588926","application-of-18f-fdg-petmri-for-initial-staging-in-locally-advanced-nasopharyngeal-carcinoma-100588926",false,"NCT06947759","Application of 18F-FDG PET\u002FMRI for Initial Staging in Locally Advanced Nasopharyngeal Carcinoma","Application of 18F-FDG PET\u002FMRI as an Initial Staging Procedure for Locally Advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Pathologically diagnosed with nasopharyngeal carcinoma (NPC) through endoscopic biopsy at the hospital's otolaryngology department.\n* Clinically staged as cT3-4\u002FN2-N3.\n* Age: 18 years and older.\n* Participants must voluntarily sign an informed consent form, acknowledging understanding of the study objectives and potential risks.\n\nExclusion Criteria:\n\n* Patients with poorly controlled diabetes. -Patients with a history of head and neck malignancies or a history of non- head and neck cancers with no evidence of disease for at least 3 years.\n* Patients with clinical staging of cT1-2N0-1.\n* Patients with factors that may affect PET\u002FMRI image quality, such as implanted metal devices or MRI contraindications, or those with a history of contrast agent allergies.","ALL","18 Years",{"count":46,"type":47},20,"ESTIMATED","OBSERVATIONAL","This single-center prospective observational study aims to evaluate the feasibility, cost-effectiveness, and clinical value of positron emission tomography\u002Fmagnetic resonance imaging (PET\u002FMRI) for initial staging in patients with locally advanced nasopharyngeal carcinoma (NPC). It will compare the diagnostic performance of PET\u002FMRI, including sensitivity, specificity, and staging accuracy, with traditional staging methods such as positron emission tomography\u002Fcomputed tomography (PET\u002FCT).\n\nNasopharyngeal carcinoma is prevalent in Southeast Asia and North Africa, with approximately 5% of newly diagnosed cases presenting with distant metastases. For patients with N2-3 disease and elevated Epstein-Barr virus (EBV) DNA levels, the risk of distant metastasis can reach 27.5%. Accurate detection of distant metastases at diagnosis is crucial for staging and treatment planning. Current National Comprehensive Cancer Network (NCCN) guidelines recommend fluorodeoxyglucose (18F-FDG) PET\u002FCT for staging in locally advanced nasopharyngeal carcinoma, as traditional tools (e.g., chest CT, abdominal ultrasound, bone scans) may yield false-negative results.\n\nPET\u002FMRI, as a novel imaging technique, offers potential advantages such as improved diagnostic accuracy, shorter scan times, and reduced false-positive rates. However, its clinical application is limited by high costs and equipment availability. This study will explore the clinical value and economic feasibility of PET\u002FMRI in nasopharyngeal carcinoma staging, aiming to establish its potential role in improving diagnostic pathways.",[51,52],"Nuclear Medicine","Oncology",[11,54,55],"Nasopharyngeal carcinoma","EBV DNA","NOT_YET_RECRUITING","2025-04-23",{"date":59,"type":60},"2025-04-27","ACTUAL",{"date":62,"type":47},"2025-04-30",{"date":64,"type":47},"2026-04-30",{"name":5,"class":6},1]